Form 4: ClearPoint Neuro Director Lynnette C. Fallon Reports Stock Transactions

Sentiment:

SEC Form 4


Director Lynnette C. Fallon reports the conversion of restricted stock units into common stock and subsequent disposal of shares.

Summary

  • On May 14, 2024, Lynnette C. Fallon, a director of ClearPoint Neuro, Inc., converted 17,153 restricted stock units into common stock.
  • Following the conversion, Ms. Fallon disposed of 30,008 shares of common stock.
  • After these transactions, Ms. Fallon still beneficially owns an unspecified amount of common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates

DateDescription
05/25/2023Reporting person was granted 17,153 restricted stock units.
05/14/2024Reporting person converted restricted stock units to common stock and disposed of shares.
05/15/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.